New draft guidance issued by FDA on developing drugs for Alzheimer's disease

Source: FDA Area: News The FDA has issued draft guidance designed to assist manufacturing companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of noticeable dementia.   The draft guidance titled, "Guidance for Industry, Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease," explains the FDA's current thinking about the way researchers can identify and select patients with early Alzheimer's disease, or those who are at risk of developing the disease, for participation in clinical trials.
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news